Top-News
Pharmazeutika Schweiz

Novartis AG ADR

Aktie
WKN:  907122 ISIN:  US66987V1098 US-Symbol:  NVS
95,00 €
+0,00 €
0,00%
17.01.25
Handeln Depot/Watchlist
Aktienanzahl *
1,99 Mrd.
Marktkapitalisierung *
198,01 Mrd. €
Streubesitz
79,02%
Faktor
1
Originalaktie
CH0012005267
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 11.12.2023

Novartis AG ADR News

02.12.24 - PR Newswire
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR Newswire
18.11.24 - PR Newswire
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate PR Newswire
18.10.24 - PR Newswire
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR Newswire
07.08.24 - PR Newswire
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) PR ...
25.05.24 - PR Newswire
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire
25.05.24 - PR Newswire
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. ...
15.04.24 - PR Newswire
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy ...
06.04.24 - PR Newswire
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
New Novartis data show early addition of twice-​yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-​world ...
10.12.23 - PR Newswire
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal ...
06.12.23 - PR Newswire
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with ...
16.09.23 - Small- & Micro Cap Investment
Eine Industrie im Rausch: Green Rush an der Börse – Tilray, Water Ways und SynBiotic sind dabei
Eine komplette Industrie ist im Rausch. Vor rund 80 Jahren war Cannabis fast überall auf der Welt verboten. Nun öffnen sich nach und nach die Türen, welche auf einen Markt ...
11.09.23 - PR Newswire
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization PR Newswire
10.09.23 - Julius Weiß
Wochenausblick – Trotz hartnäckiger Inflation sind Anleger positiv gestimmt
Zum Start in die neue Börsenwoche informieren wir jeden Sonntag über Wirt­schafts­daten, Quartals­zahlen und mehr. Neben den Arbeits­markt­daten aus UK und  dem EZB-...
30.08.23 - PR Newswire
Thinking about trading options or stock in NVIDIA, SoundHound AI, Novartis, Faraday Future Intelligent Electric, or Medical Properties Trust?
Thinking about trading options or stock in NVIDIA, SoundHound AI, Novartis, Faraday Future Intelligent Electric, or Medical Properties Trust? PR Newswire
08.06.23 - PR Newswire
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-​MUTANT GRADE 2 & 3 GLIOMA PR Newswire
20.05.23 - Small- & Micro Cap Investment
Water Ways: Aktien des Green Rush: Cannabis-Markt auf dem Vormarsch – Tilray, Water Ways und SynBiotic halten Schritt
Eine komplette Industrie ist im Rausch. Vor rund 80 Jahren war Cannabis fast überall auf der Welt verboten. Nun öffnen sich nach und nach die Türen, welche auf einen Markt ...
25.04.23 - PR Newswire
Thinking about trading options or stock in Spotify Technology, Novartis, Apple, UnitedHealth Group, or Honeywell?
Thinking about trading options or stock in Spotify Technology, Novartis, Apple, UnitedHealth Group, or Honeywell? PR Newswire
18.04.23 - Small- & Micro Cap Investment
Water Ways: Aktien des Green Rush: Cannabis-Markt auf dem Vormarsch – Tilray, Water Ways und SynBiotic halten Schritt
Eine komplette Industrie ist im Rausch. Vor rund 80 Jahren war Cannabis fast überall auf der Welt verboten. Nun öffnen sich nach und nach die Türen, welche auf einen Markt ...
05.03.23 - Small- & Micro Cap Investment
Water Ways: Aktien des Green Rush: Cannabis-Markt auf dem Vormarsch – Tilray, Water Ways und SynBiotic halten Schritt
Eine komplette Industrie ist im Rausch. Vor rund 80 Jahren war Cannabis fast überall auf der Welt verboten. Nun öffnen sich nach und nach die Türen, welche auf einen Markt ...
21.11.22 - PR Newswire
Thinking about trading options or stock in AstraZeneca, Jacobs Solutions, J M Smucker, Tesla, or Novartis?
Thinking about trading options or stock in AstraZeneca, Jacobs Solutions, J M Smucker, Tesla, or Novartis? PR Newswire

Newssuche

Videos

newspaper
16.01.25 +3,48%
Technical Trading: Gold mit neuer Long Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 7 Laufzeit: OpenEnd Einstieg: Market ... Mehr »